{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:45:18Z","timestamp":1787168718184,"version":"build-2736575974"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:00:00Z","timestamp":1632960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:00:00Z","timestamp":1632960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Testing for antibodies against podocyte phospholipase A2 receptor-1 (PLA2R) allows clinicians to accurately identify primary membranous nephropathy (MN). Secondary MN is associated with a spectrum of pathology including solid organ malignancy. PLA2R positivity in these patients occurs, although no case of PLA2R-positive MN has been definitively linked to cancer.<\/jats:p>\n <\/jats:sec>\n \n Case presentation<\/jats:title>\n We describe a case of biopsy-proven PLA2R-positive MN, in whom invasive ductal carcinoma of the breast was discovered. The patient underwent surgery and adjuvant chemotherapy (including cyclophosphamide) and went into a sustained complete remission of her nephrotic syndrome.<\/jats:p>\n <\/jats:sec>\n \n Discussion and conclusions<\/jats:title>\n Case series have reported PLA2R positivity in patients with solid organ malignancy associated MN. Our case is unusual as it is a breast malignancy, and the patients nephrotic syndrome and anti-PLA2Rab titres improved with treatment of the cancer. Here we report, to the best of our knowledge, the first case of oestrogen receptor-2 positive breast cancer associated with PLA2R positive MN in a young lady that was treated successfully by treating the malignancy.<\/jats:p>\n <\/jats:sec>","DOI":"10.1186\/s12882-021-02511-x","type":"journal-article","created":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T01:03:54Z","timestamp":1632963834000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A case report of breast cancer and membranous nephropathy with positive anti phospholipase A2 receptor antibodies"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6125-212X","authenticated-orcid":false,"given":"David","family":"Mathew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjana","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Ashman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,30]]},"reference":[{"issue":"1","key":"2511_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","volume":"361","author":"LH Beck","year":"2009","unstructured":"Beck LH. Jr1, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa0810457.","journal-title":"N Engl J Med"},{"issue":"8","key":"2511_CR2","doi-asserted-by":"publisher","first-page":"e104936","DOI":"10.1371\/journal.pone.0104936","volume":"9","author":"Y Du","year":"2014","unstructured":"Du Y, Li J, He F, et al. The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy: a meta-analysis. PLoS One. 2014;9(8):e104936. https:\/\/doi.org\/10.1371\/journal.pone.0104936.","journal-title":"PLoS One"},{"issue":"6","key":"2511_CR3","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1681\/ASN.2010090967","volume":"22","author":"W Qin","year":"2011","unstructured":"Qin W, Beck LH Jr, Zeng C, Chen Z, Li S, Zuo K, et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol. 2011;22(6):1137\u201343. https:\/\/doi.org\/10.1681\/ASN.2010090967 Epub 2011 May.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"2511_CR4","doi-asserted-by":"publisher","first-page":"943","DOI":"10.34067\/KID.0002802020","volume":"1","author":"L Luzardo","year":"2020","unstructured":"Luzardo L, Ottati G, Cabrera J, Trujillo H, Garau M, Caorsi, et al. Substitution of oral for intravenous cyclophosphamide in membranous nephropathy. Kidney360. 2020;1(9):943\u20139.","journal-title":"Kidney360"},{"key":"2511_CR5","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMc1511702","volume":"374","author":"E Hoxha","year":"2016","unstructured":"Hoxha E, Wiech T, Stahl PR, Zahner G, Panzer U, Thomas NM, et al. A Mechanism for Cancer-Associated Membranous Nephropathy. N. Engl. J. Med. 2016;374:1995\u20136.","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"2511_CR6","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.kint.2020.07.039","volume":"99","author":"T Caza","year":"2021","unstructured":"Caza T, Hassen S, Dvanajscak Z, Kuperman M, Edmondson R, Larsen P, et al. NELL1 is a target antigen in malignancy-associated membranous nephropathy. Kidney Int. 2021;99(4):967\u201376. https:\/\/doi.org\/10.1016\/j.kint.2020.07.039 Epub 2020 Aug 20.","journal-title":"Kidney Int"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02511-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-021-02511-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02511-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T01:12:28Z","timestamp":1632964348000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-021-02511-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,30]]},"references-count":6,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2511"],"URL":"https:\/\/doi.org\/10.1186\/s12882-021-02511-x","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,30]]},"assertion":[{"value":"15 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethics approval was required for this case presentation.<\/b>","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written consent was obtained was obtained for the publication of this case report from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"324"}}